Lewis Sara Grootwassink

Director Lewis Sara Grootwassink bought 4,500 shares of WY at $23.61, increasing holdings 21.0% to 26.0K shares

Director Lewis Sara Grootwassink purchased 4,500 shares at $23.61 on 2025-12-17, a substantial 21.0% increase to her post-transaction holdings of 26.0K shares. The transaction occurred near the lower end of the 52-week range ($21.35–$31.39), with the stock currently at $23.60 and down 24.8% from its 52-week high. However, her track record at this ticker is cautionary: her single prior buy at WY on 2025-08-11 delivered a 90-day return of -8.7%, and her cross-ticker history shows a 50% win rate at the 90-day mark despite an average 90-day return of +7.9%. Fundamental headwinds are present—annual revenue declined 7.2% year-over-year, and the company trades at a P/E of 51.30 on net income of $80.0M against a market cap of $17.0B.

Director Lewis Sara Grootwassink bought 4,000 shares (4.0K) of WY at $25.28; stock now -22.0% from 52-week high.

Director Grootwassink purchased 4,000 shares for $101,140.00, increasing her holdings by 22.9% to 21,478 shares total. The transaction occurred at $25.28, below the current price of $26.41 and well below the 52-week high of $33.86. Weyerhaeuser faces headwinds with annual revenue declining 7.2% and a high P/E of 67.72, yet Grootwassink's cross-ticker track record shows 3 prior purchases averaging a 13.4% 90-day return with a 66.67% win rate. This purchase represents a material accumulation by a director during a period when the stock trades significantly below its year-high valuation.

Director Sara Grootwassink buys 6,000 DOC shares at $17.66; 4 other insiders bought in past 14 days

Lewis Sara Grootwassink, a Director, purchased 6,000 shares of HEALTHPEAK PROPERTIES, INC. at $17.66 on 2025-04-28, tripling her position from 3,000 to 9,000 shares for a total value of $105,938.40. This purchase occurs within a broader cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated or convergent conviction among the leadership group. The transaction is priced near the 52-week low (current price $17.75 is -23.2% from the 52-week high of $23.12), and the insider's prior buy at this ticker on 2024-03-04 subsequently returned +19.1% over 90 days, indicating a history of well-timed entry points. The company's fundamentals show revenue of $702,889,000.00 and annual revenue growth of +23.8%, though the elevated P/E of 44.38 reflects market expectations not yet earned out in recent net income of $42,828,000.00.